Today: 31 January 2026
Subscribe
Browse Category

Earnings Reports News 6 November 2025

Vistra (VST) Q3 2025: $652M Profit, 2026 EBITDA Outlook Raised to $6.8–$7.6B; Board Adds $1B Buyback

Vistra (VST) Q3 2025: $652M Profit, 2026 EBITDA Outlook Raised to $6.8–$7.6B; Board Adds $1B Buyback

What Vistra reported today Vistra posted third‑quarter 2025 GAAP net income of $652 million and Ongoing Operations Adjusted EBITDA of $1.581 billion. Management said the year‑over‑year decline in GAAP profit primarily reflects lower unrealized mark‑to‑market gains on hedging positions and the Martin Lake Unit 1 outage, partially offset by recognition of nuclear production tax credit revenue and firmer capacity prices.…
6 November 2025
···
Stagwell (STGW) Soars After Q3 Beat and Palantir AI Partnership; 2025 Outlook Calls for ~8% Net Revenue Growth (Nov. 6, 2025)

Stagwell (STGW) Soars After Q3 Beat and Palantir AI Partnership; 2025 Outlook Calls for ~8% Net Revenue Growth (Nov. 6, 2025)

What’s new today Earnings: Stagwell Inc. (NASDAQ: STGW) reported third‑quarter revenue of $743 million, GAAP EPS of $0.09, and adjusted EPS of $0.24. Management highlighted double‑digit “ex‑advocacy” momentum, with net revenue ex‑advocacy up 10% to $578 million, and adjusted EBITDA of $115 million (19% margin on net revenue). The company also pointed to $122 million in net new business for…
6 November 2025
···
Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported third‑quarter 2025 results this morning (Nov. 6), highlighting sequential revenue growth, materially higher gross margins, and steady commercial momentum for its tumor‑infiltrating lymphocyte (TIL) therapy Amtagvi. Management also reaffirmed full‑year revenue guidance and flagged pipeline milestones led by encouraging lung‑cancer data for lifileucel. GlobeNewswire What Iovance announced (Nov. 6, 2025) Revenue, margin, and guidance.…
6 November 2025
····
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

What happened today Novavax, Inc. (NASDAQ: NVAX) reported Q3 2025 results and raised its full‑year adjusted revenue framework to $1.04–$1.06 billion (from $1.00–$1.05 billion). Management cited momentum from licensing, supply, and milestone revenue—while excluding Sanofi‑led sales and royalties from the outlook. The company also reaffirmed 2025 operating‑expense guidance. Novavax Revenue for the quarter came in at $70 million, above Wall…
6 November 2025
····
Fortinet (FTNT) slips on soft Q4 outlook after Q3 beat; price targets trimmed as company unveils “Secure AI Data Center” — Nov. 6, 2025

Fortinet (FTNT) slips on soft Q4 outlook after Q3 beat; price targets trimmed as company unveils “Secure AI Data Center” — Nov. 6, 2025

Earnings snapshot: strong quarter, but guidance cools sentiment What happened: Fortinet’s September‑quarter (Q3 FY25) revenue rose ~14% to ~$1.72B with adjusted EPS at $0.74 (vs. ~$0.63 expected). Billings—a forward demand proxy—also climbed ~14% to ~$1.81B. After the report, investors focused on the softer Q4 guide, which ran a touch below consensus and drove the shares lower in late trading. Investors…
6 November 2025
····
AppLovin (APP) soars ~7% after blowout Q3 2025: revenue up 68%, buyback boosted by $3.2B, and Wedbush lifts price target to $800

AppLovin (APP) soars ~7% after blowout Q3 2025: revenue up 68%, buyback boosted by $3.2B, and Wedbush lifts price target to $800

AppLovin Corporation (NASDAQ: APP) is rallying today after reporting another set of blockbuster results and raising its buyback firepower. Shares were up roughly 7%–8% in Thursday trading as investors digested the company’s stronger‑than‑expected Q3 print and upbeat Q4 outlook, while sell‑side analysts raised targets. Barron’s Key takeaways What happened in Q3 (ended Sept. 30, 2025) AppLovin’s top and bottom lines…
6 November 2025
···
DoorDash (DASH) plunges as 2026 spending plan eclipses Q3 beat — What to know today (Nov 6, 2025)

DoorDash (DASH) plunges as 2026 spending plan eclipses Q3 beat — What to know today (Nov 6, 2025)

DoorDash, Inc. (NASDAQ: DASH) is under pressure today after the delivery platform beat Q3 revenue and order-growth expectations but told investors it will spend “several hundred million dollars more” in 2026 to accelerate a new global tech platform and other initiatives. Shares fell sharply in after‑hours trading last night and were down again in early trading today as Wall Street…
6 November 2025
···
D‑Wave Quantum (QBTS) Q3 2025: Revenue Doubles to $3.7M, Record $836M Cash, Bookings Accelerate — What It Means for the Stock Today

D‑Wave Quantum (QBTS) Q3 2025: Revenue Doubles to $3.7M, Record $836M Cash, Bookings Accelerate — What It Means for the Stock Today

D‑Wave Quantum Inc. (NYSE: QBTS) reported third‑quarter fiscal 2025 results before the open today, delivering 100% year‑over‑year revenue growth to $3.7 million and a sharp sequential uptick in customer bookings to $2.4 million. Shares were recently around $31 intraday, modestly higher following the print. The company also ended the quarter with a record $836.2 million cash balance, while GAAP net…
6 November 2025
····
Arm Holdings (ARM) Beats Q2, Lifts Q3 Outlook on AI Momentum — What to Know Today (Nov. 6, 2025)

Arm Holdings (ARM) Beats Q2, Lifts Q3 Outlook on AI Momentum — What to Know Today (Nov. 6, 2025)

Why Arm is rallying today Arm delivered another “beat‑and‑raise” quarter as AI workloads continue to shift toward Arm’s power‑efficient compute. Revenue of $1.14B (+34% YoY) topped expectations, while non‑GAAP EPS of $0.39 cleared the Street. Management guided Q3 well above consensus, citing broad‑based strength across smartphones, automotive, IoT—and especially data centers, where hyperscalers are standardizing around Arm for performance‑per‑watt gains.…
6 November 2025
····
e.l.f. Beauty (ELF) plunges as tariff hit and soft FY‑2026 outlook overshadow Rhode boost: what to know today (Nov. 6, 2025)

e.l.f. Beauty (ELF) plunges as tariff hit and soft FY‑2026 outlook overshadow Rhode boost: what to know today (Nov. 6, 2025)

What happened e.l.f. Beauty’s stock is tumbling today after the company’s fiscal Q2 print and FY‑2026 guidance underwhelmed investors. In last night’s release, management guided to $1.55–$1.57 billion in sales and $2.80–$2.85 adjusted EPS for FY‑2026, short of consensus (~$1.65B and ~$3.58). The outlook reflects a step‑down in profitability as U.S. import tariffs lift costs and growth in the core…
6 November 2025
··
Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

Comstock Resources (CRK) Jumps as Q3 Results, $430M Divestiture and Rising RS Rating Put Haynesville Gas in Focus — Nov. 6, 2025

FRISCO, Texas — Nov. 6, 2025. Shares of Comstock Resources, Inc. (NYSE: CRK) traded higher today after a week packed with catalysts: stronger third‑quarter results, progress on a $430 million asset sale, and a fresh technical tailwind as the stock’s Relative Strength (RS) rating ticked up. Midday, CRK changed hands around $21.14, up roughly 5.5%, within a 52‑week range of…
6 November 2025
····
Oscar Health (OSCR) Q3 2025: ~$3.0B Revenue, EPS Beats, 2025 Guidance Reaffirmed; Balance Sheet Simplified via Note Exchange — Nov. 6, 2025

Oscar Health (OSCR) Q3 2025: ~$3.0B Revenue, EPS Beats, 2025 Guidance Reaffirmed; Balance Sheet Simplified via Note Exchange — Nov. 6, 2025

What happened in Q3 Oscar Health reported third‑quarter revenue of $2,985,984,000 (in thousands), up from $2,423,482,000 a year ago—about 23% YoY growth, driven largely by higher membership. The medical loss ratio (MLR) increased to 88.5% (from 84.6%), which the company tied to a $130M net risk‑adjustment transfer accrual reflecting higher average market morbidity; this was partly offset by $84M of…
6 November 2025
···
1 … 260 261 262 263 264 … 287

Stock Market Today

  • City Developments stock dips ahead of weekend amid Newport Residences launch
    January 31, 2026, 3:32 AM EST. City Developments Limited shares fell 0.6% to close at S$9.28 on Friday, near a 52-week high, despite a 16% rally in January. The property developer is launching bookings for Newport Residences, a 246-unit condo with prices starting at S$1.298 million. CDL Hospitality Trusts reported a 1.2% rise in distributions for H2 2025. Investors will watch Monday's trading closely for post-launch signals and anticipate the company's unaudited FY2025 results release on Feb. 27. The stock's sensitivity to housing and travel sectors remains, with rising funding costs presenting additional risks amid a weaker broader market.
Go toTop